Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
new option listings on July 28th » 08:30
07/28/21
07/28
08:30
07/28/21
08:30
ACHV

Achieve Life Sciences

$7.29 /

-0.35 (-4.58%)

, ADES

Advanced Emissions

$7.42 /

+0.27 (+3.78%)

, ALGS

Aligos Therapeutics

$15.07 /

-0.43 (-2.77%)

, ATCX

Atlas Technical Consultants

$8.98 /

-0.45 (-4.77%)

, BBCP

Concrete Pumping

$8.61 /

+0.13 (+1.53%)

, BTTR

Better Choice Company

$3.47 /

-0.45 (-11.48%)

, CDAK

Codiak

$16.35 /

-0.11 (-0.67%)

, CGA

China Green

$9.65 /

-0.51 (-5.02%)

, CHMI

Cherry Hill Mortgage

$9.42 /

+0.04 (+0.43%)

, CRCT

Cricut

$34.01 /

-3.02 (-8.16%)

, CRTD

Creatd

$3.17 /

-0.01 (-0.31%)

, DRTT

Dirtt Environmental

$4.18 /

+0.03 (+0.72%)

, EARN

Ellington Residential

$11.12 /

-0.06 (-0.54%)

, EPS

WisdomTree Earnings 500

$47.00 /

-0.3 (-0.63%)

, ESXB

Community Bankers Trust

$10.65 /

-0.06 (-0.56%)

, EZM

E-Z-EM

$51.80 /

-0.15 (-0.29%)

, HMLP

Hoegh LNG Partners

$17.76 /

-0.11 (-0.62%)

, ICL

ICL

$7.06 /

-0.07 (-0.98%)

, IMXI

International Money Express

$15.76 /

-0.09 (-0.57%)

, INTT

inTEST

$13.53 /

-0.65 (-4.58%)

, LIQT

LiqTech

$6.40 /

+0.19 (+3.06%)

, MDWD

MediWound

$4.08 /

+0.26 (+6.81%)

, PSJ

PwerShares Dynamic Software

$157.72 /

-2.98 (-1.85%)

, RTPY

Reinvent Technology Partners Y

$9.91 /

-0.02 (-0.20%)

, SGTX

Sigilon Therapeutics

$5.31 /

+0.32 (+6.41%)

, SIC

Select Interior Concepts

$10.47 /

+0.18 (+1.75%)

, USDP

USD Partners

$6.66 /

-0.16 (-2.35%)

, VIRI

Virios Therapeutics

$5.64 /

-0.06 (-1.05%)

, VYGG

Vy Global Growth

$9.79 /

-0.04 (-0.41%)

New option listings for…

New option listings for July 28th include Achieve Life Sciences Inc (ACHV), Advanced Emissions (ADES), Market Vectors Africa (AFK), Aligos Therapeutics Inc (ALGS), Atlas Technical Consultants Inc (Class A Stock) (ATCX), Concrete Pumping Holdings Inc (BBCP), Better Choice Company Inc (BTTR), CBX (CBX), Codiak BioSciences Inc (CDAK), China Green (CGA), Cherry Hill Mortgage (CHMI), Cricut Inc (CRCT), Creatd Inc (CRTD), WisdomTree High Dividend Fund (DHS), Dirtt Environmental Solutions Ltd (DRTT), Ellington Residential (EARN), WisdomTree SmallCap Earnings Fund (EES), WisdomTree Earnings 500 Fund (EPS), Community Bankers Trust (ESXB), WisdomTree MidCap Earnings Fund (EZM), Hoegh LNG (HMLP), IBO (IBO), Israel Chemicals (ICL), iShares Evolved US Technology ETF (IETC), iShares Edge MSCI Intl Momentum Factor ETF (IMTM), International Money Express Inc (IMXI), inTest (INTT), WisdomTree International Quality Dividend Growth Fund (IQDG), iShares Russell Top 200 (IWL), iShares Russell Top 200 Value (IWX), iShares Dow Jones US (IYY), SPDR Russell 1000 Low Volatility ETF (LGLV), LiqTech (LIQT), MediWound (MDWD), Power Shares Food And Beverage (PBJ), PowerShares S&P 500 Buy Write Portfolio (PBP), PowerShares Dynamic Media Portfolio (PBS), PowerShares FTSE RAFI Developed Markets Ex US Sm Mid Portfolio (PDN), PowerShares Dynamic Building and Construction Portfolio (PKB), PowerShares S&P SmallCap Consumer Discretionary Portfolio (PSCD), Power Shares Dynamic Software Portfolio (PSJ), Powershares Dynamic Large Cap Growth Portfolio (PWB), Powershares Dynamic Large Cap Value Portfolio (PWV), PowerShares FTSE RAFI Developed Markets ex US Portfolio (PXF), PowerShares DWA Basic Materials Momentum Portfolio (PYZ), Reinvent Technology Partners Y (Class A Stock) (RTPY), Sigilon Therapeutics Inc (SGTX), Select Interior Concepts Inc (Class A Stock) (SIC), Presidio Property Trust Inc (Class A Stock) (SQFT), USD Partners (USDP), Virios Therapeutics Inc (VIRI), Vy Global Growth (Class A Stock) (VYGG), WisdomTree Cybersecurity Fund (WCBR), Innovative Technology ETF (XITK), and SPDR NYSE Technology (XNTK).

ShowHide Related Items >><<
VIRI Virios Therapeutics
$5.64 /

-0.06 (-1.05%)

USDP USD Partners
$6.66 /

-0.16 (-2.35%)

SIC Select Interior Concepts
$10.47 /

+0.18 (+1.75%)

SGTX Sigilon Therapeutics
$5.31 /

+0.32 (+6.41%)

RTPY Reinvent Technology Partners Y
$9.91 /

-0.02 (-0.20%)

MDWD MediWound
$4.08 /

+0.26 (+6.81%)

INTT inTEST
$13.53 /

-0.65 (-4.58%)

IMXI International Money Express
$15.76 /

-0.09 (-0.57%)

ICL ICL
$7.06 /

-0.07 (-0.98%)

HMLP Hoegh LNG Partners
$17.76 /

-0.11 (-0.62%)

ESXB Community Bankers Trust
$10.65 /

-0.06 (-0.56%)

EARN Ellington Residential
$11.12 /

-0.06 (-0.54%)

DRTT Dirtt Environmental
$4.18 /

+0.03 (+0.72%)

CRTD Creatd
$3.17 /

-0.01 (-0.31%)

CRCT Cricut
$34.01 /

-3.02 (-8.16%)

CGA China Green
$9.65 /

-0.51 (-5.02%)

CDAK Codiak
$16.35 /

-0.11 (-0.67%)

BTTR Better Choice Company
$3.47 /

-0.45 (-11.48%)

BBCP Concrete Pumping
$8.61 /

+0.13 (+1.53%)

ATCX Atlas Technical Consultants
$8.98 /

-0.45 (-4.77%)

ALGS Aligos Therapeutics
$15.07 /

-0.43 (-2.77%)

ADES Advanced Emissions
$7.42 /

+0.27 (+3.78%)

ACHV Achieve Life Sciences
$7.29 /

-0.35 (-4.58%)

ACHV Achieve Life Sciences
$7.29 /

-0.35 (-4.58%)

07/22/21 Lake Street
NIH grant opens new opportunity for Achieve's cytisinicline, says Lake Street
07/20/21 Lake Street
Achieve Life weakness on Chantix news would be opportunity, says Lake Street
07/06/21 Lake Street
Achieve Life Sciences weakness a buying opportunity, says Lake Street
06/25/21 Lake Street
Achieve Life Sciences not hurt by Chantix recall, says Lake Street
ADES Advanced Emissions
$7.42 /

+0.27 (+3.78%)

ALGS Aligos Therapeutics
$15.07 /

-0.43 (-2.77%)

07/08/21 Piper Sandler
Aligos should be bought into 'catalyst rich' second half, says Piper Sandler
06/21/21 Piper Sandler
Aligos reported 'robust data' in hepatitis B virus, says Piper Sandler
06/10/21 Piper Sandler
Aligos Therapeutics has data-rich month with robust lineup, says Piper Sandler
05/17/21 Piper Sandler
Aligos Therapeutics assumed with an Overweight at Piper Sandler
ATCX Atlas Technical Consultants
$8.98 /

-0.45 (-4.77%)

01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Stifel
Atlas Technical Consultants initiated with a Buy at Stifel
08/11/20 DA Davidson
Atlas Technical Consultants upgraded to Buy from Neutral at DA Davidson
08/11/20 DA Davidson
Atlas Technical Consultants upgraded to Buy from Neutral at DA Davidson
BBCP Concrete Pumping
$8.61 /

+0.13 (+1.53%)

06/25/21 UBS
Concrete Pumping upgraded to Buy from Neutral at UBS
06/16/21 DA Davidson
Concrete Pumping price target raised to $11 from $9 at DA Davidson
06/15/21 Baird
Concrete Pumping price target raised to $11 from $10 at Baird
04/22/21 Baird
Concrete Pumping price target raised to $9 from $8 at Baird
BTTR Better Choice Company
$3.47 /

-0.45 (-11.48%)

07/26/21 Roth Capital
Better Choice Company initiated with a Buy at Roth Capital
07/15/21 DA Davidson
Better Choice Company initiated with a Buy at DA Davidson
07/15/21 DA Davidson
Better Choice Company initiated with a Buy at DA Davidson
CDAK Codiak
$16.35 /

-0.11 (-0.67%)

12/31/20 Wedbush
Codiak price target raised to $31 from $19 at Wedbush
11/09/20
Fly Intel: Top five analyst initiations
11/09/20 Wedbush
Codiak initiated with an Outperform at Wedbush
11/08/20 Goldman Sachs
Codiak initiated with a Buy at Goldman Sachs
CGA China Green
$9.65 /

-0.51 (-5.02%)

CHMI Cherry Hill Mortgage
$9.42 /

+0.04 (+0.43%)

04/20/21 B. Riley
Cherry Hill Mortgage transferred with Buy, $11.50 target at B. Riley
11/10/20 Piper Sandler
Cherry Hill Mortgage downgraded to Neutral from Overweight at Piper Sandler
CRCT Cricut
$34.01 /

-3.02 (-8.16%)

06/10/21 Morgan Stanley
Cricut downgraded to Equal Weight from Overweight at Morgan Stanley
05/14/21 Barclays
Cricut price target raised to $28 from $26 at Barclays
04/19/21
Fly Intel: Top five analyst initiations
04/19/21 Citi
Cricut initiated with a Buy at Citi
CRTD Creatd
$3.17 /

-0.01 (-0.31%)

DRTT Dirtt Environmental
$4.18 /

+0.03 (+0.72%)

05/06/21 National Bank
Dirtt Environmental downgraded to Sector Perform from Outperform at National Bank
05/06/21 National Bank
Dirtt downgraded to Sector Perform from Outperform at National Bank
12/31/20
Fly Intel: Top five analyst calls
12/31/20 Industrial Alliance
DIRTT Environmental downgraded to Sell from Hold at Industrial Alliance
EARN Ellington Residential
$11.12 /

-0.06 (-0.54%)

11/23/20 BTIG
Ellington Residential initiated with a Buy at BTIG
EPS WisdomTree Earnings 500
$47.00 /

-0.3 (-0.63%)

ESXB Community Bankers Trust
$10.65 /

-0.06 (-0.56%)

02/03/21 Stephens
Stephens cuts Community Bankers Trust to Equal Weight as stock nears $8 target
02/03/21 Stephens
Community Bankers Trust downgraded to Equal Weight from Overweight at Stephens
EZM E-Z-EM
$51.80 /

-0.15 (-0.29%)

HMLP Hoegh LNG Partners
$17.76 /

-0.11 (-0.62%)

07/28/21 B. Riley
Hoegh LNG Partners downgraded to Neutral from Buy at B. Riley
07/28/21 B. Riley
Hoegh LNG Partners downgraded to Neutral from Buy at B. Riley
07/28/21 Barclays
Hoegh LNG Partners downgraded to Underweight from Overweight at Barclays
03/10/21 Danske Bank
Hoegh LNG Partners upgraded to Hold from Sell at Danske Bank
ICL ICL
$7.06 /

-0.07 (-0.98%)

11/23/20 Stephens
ICL downgraded to Equal Weight with $5.50 price target at Stephens
11/23/20 Stephens
ICL downgraded to Equal Weight from Overweight at Stephens
IMXI International Money Express
$15.76 /

-0.09 (-0.57%)

05/05/21 BTIG
International Money earnings selloff a buying opportunity, says BTIG
08/17/20 BTIG
International Money Express price target raised to $22 from $17 at BTIG
08/05/20 Cantor Fitzgerald
International Money price target raised to $21 from $11 at Cantor Fitzgerald
08/05/20 JMP Securities
International Money Express upgraded to Outperform at JMP Securities
INTT inTEST
$13.53 /

-0.65 (-4.58%)

05/10/21 Lake Street
inTEST price target raised to $16 from $11 at Lake Street
03/08/21 Lake Street
inTEST price target raised to $11 from $6 at Lake Street
LIQT LiqTech
$6.40 /

+0.19 (+3.06%)

10/15/20 Stephens
LiqTech resumed with an Equal Weight at Stephens
10/02/20 B. Riley
LiqTech price target raised to $11 from $8 at B. Riley Securities
MDWD MediWound
$4.08 /

+0.26 (+6.81%)

06/29/21 Oppenheimer
MediWound NexoBrid CRL as expected, says Oppenheimer
03/02/21 Aegis
MediWound initiated with a Buy at Aegis
02/26/21 H.C. Wainwright
MediWound price target raised to $7 from $5.50 at H.C. Wainwright
10/19/20 BTIG
Vericel price target raised to $30 from $23 at BTIG
PSJ PwerShares Dynamic Software
$157.72 /

-2.98 (-1.85%)

RTPY Reinvent Technology Partners Y
$9.91 /

-0.02 (-0.20%)

SGTX Sigilon Therapeutics
$5.31 /

+0.32 (+6.41%)

07/19/21 Canaccord
Sigilon Therapeutics price target lowered to $43 from $62 at Canaccord
12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
SIC Select Interior Concepts
$10.47 /

+0.18 (+1.75%)

03/16/21 B. Riley
Select Interior Concepts price target raised to $14 from $13 at B. Riley
02/02/21 B. Riley
Select Interior looks attractive relative to Blackstone deal, says B. Riley
01/22/21 B. Riley
Select Interior Concepts price target raised to $13 from $12 at B. Riley
09/11/20 Truist
Select Interior Concepts initiated with a Buy at Truist
USDP USD Partners
$6.66 /

-0.16 (-2.35%)

VIRI Virios Therapeutics
$5.64 /

-0.06 (-1.05%)

VYGG Vy Global Growth
$9.79 /

-0.04 (-0.41%)

SIC Select Interior Concepts
$10.47 /

+0.18 (+1.75%)

SGTX Sigilon Therapeutics
$5.31 /

+0.32 (+6.41%)

MDWD MediWound
$4.08 /

+0.26 (+6.81%)

LIQT LiqTech
$6.40 /

+0.19 (+3.06%)

INTT inTEST
$13.53 /

-0.65 (-4.58%)

IMXI International Money Express
$15.76 /

-0.09 (-0.57%)

ICL ICL
$7.06 /

-0.07 (-0.98%)

HMLP Hoegh LNG Partners
$17.76 /

-0.11 (-0.62%)

ESXB Community Bankers Trust
$10.65 /

-0.06 (-0.56%)

EARN Ellington Residential
$11.12 /

-0.06 (-0.54%)

CRTD Creatd
$3.17 /

-0.01 (-0.31%)

CHMI Cherry Hill Mortgage
$9.42 /

+0.04 (+0.43%)

CDAK Codiak
$16.35 /

-0.11 (-0.67%)

BTTR Better Choice Company
$3.47 /

-0.45 (-11.48%)

BBCP Concrete Pumping
$8.61 /

+0.13 (+1.53%)

ALGS Aligos Therapeutics
$15.07 /

-0.43 (-2.77%)

  • 29
    Jun
  • 01
    Jul
  • 17
    Jun
  • 15
    Jun
  • 25
    May
  • 25
    Mar
  • 12
    Feb
  • 17
    Dec
  • 03
    Dec
  • 04
    Dec
  • 16
    Oct
  • 14
    Oct
  • 01
    Oct
  • 14
    Aug
RTPY Reinvent Technology Partners Y
$9.91 /

-0.02 (-0.20%)

SGTX Sigilon Therapeutics
$5.31 /

+0.32 (+6.41%)

RTPY Reinvent Technology Partners Y
$9.91 /

-0.02 (-0.20%)

MDWD MediWound
$4.08 /

+0.26 (+6.81%)

INTT inTEST
$13.53 /

-0.65 (-4.58%)

ESXB Community Bankers Trust
$10.65 /

-0.06 (-0.56%)

DRTT Dirtt Environmental
$4.18 /

+0.03 (+0.72%)

CRTD Creatd
$3.17 /

-0.01 (-0.31%)

CRCT Cricut
$34.01 /

-3.02 (-8.16%)

CDAK Codiak
$16.35 /

-0.11 (-0.67%)

BBCP Concrete Pumping
$8.61 /

+0.13 (+1.53%)

ACHV Achieve Life Sciences
$7.29 /

-0.35 (-4.58%)

Over a week ago
Hot Stocks
Sigilon Therapeutics presents preclinical data on MPS, related diseases » 07:05
07/23/21
07/23
07:05
07/23/21
07:05
SGTX

Sigilon Therapeutics

$5.52 /

-0.46 (-7.69%)

Sigilon Therapeutic…

Sigilon Therapeutic reported results from several ongoing preclinical studies in the rare lysosomal diseases MPS-1, MPS-2, and MPS-6. Three scientific abstracts were selected for presentation-including an oral presentation on MPS-1-during the 16th International Symposium on MPS and Related Diseases. "Despite approved therapies for MPS-1, including hematopoietic stem cell transplantation and enzyme replacement therapy, patients experience high treatment burden and long-term disease progression," said Rogerio Vivaldi M.D., M.B.A., President and CEO of Sigilon. "While still early in its development, we are highly encouraged by these results with SIG-005, which demonstrated active IDUA production for up to 6 months in vitro and in vivo, and a dose-response relationship with tissue GAG clearance in the MPS-1H mouse model." Sigilon recently filed a Clinical Trial Application in the United Kingdom for SIG-005 in MPS-1 and anticipates submitting an Investigational New Drug application and a CTA in the United States and Brazil, respectively. If approved, Sigilon expects to initiate a Phase 1/2 clinical trial of SIG-005 in patients with MPS-1 in the second half of 2021.

ShowHide Related Items >><<
SGTX Sigilon Therapeutics
$5.52 /

-0.46 (-7.69%)

SGTX Sigilon Therapeutics
$5.52 /

-0.46 (-7.69%)

07/19/21 Canaccord
Sigilon Therapeutics price target lowered to $43 from $62 at Canaccord
12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
SGTX Sigilon Therapeutics
$5.52 /

-0.46 (-7.69%)

  • 04
    Dec
SGTX Sigilon Therapeutics
$5.52 /

-0.46 (-7.69%)

Recommendations
Sigilon Therapeutics price target lowered to $43 from $62 at Canaccord » 07:25
07/19/21
07/19
07:25
07/19/21
07:25
SGTX

Sigilon Therapeutics

$5.97 /

-0.04 (-0.67%)

Canaccord analyst…

Canaccord analyst Michelle Gilson lowered the firm's price target on Sigilon Therapeutics to $43 from $62 and keeps a Buy rating on the shares. The analyst reduced the target following the clinical hold for its therapy in hemophilia A. The analyst said its platform remains intact and key opinion leaders continue to view the product as very promising.

ShowHide Related Items >><<
SGTX Sigilon Therapeutics
$5.97 /

-0.04 (-0.67%)

SGTX Sigilon Therapeutics
$5.97 /

-0.04 (-0.67%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
SGTX Sigilon Therapeutics
$5.97 /

-0.04 (-0.67%)

  • 04
    Dec
SGTX Sigilon Therapeutics
$5.97 /

-0.04 (-0.67%)

Hot Stocks
Sigilon Therapeutics appoints Ajay Rai as SVP, head of business development » 07:02
07/19/21
07/19
07:02
07/19/21
07:02
SGTX

Sigilon Therapeutics

$5.97 /

-0.04 (-0.67%)

Sigilon Therapeutics…

Sigilon Therapeutics announced the appointment of Ajay Rai, M.B.A., as Senior Vice President, Head of Business Development. Most recently, Mr. Rai served as Vice President, Corporate Development, Strategy & Alliance Management at Frequency Therapeutics where he was responsible for evolving the company's overall business and corporate strategy and played an integral role in executing several financing rounds, including an Initial Public Offering.

ShowHide Related Items >><<
SGTX Sigilon Therapeutics
$5.97 /

-0.04 (-0.67%)

SGTX Sigilon Therapeutics
$5.97 /

-0.04 (-0.67%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
SGTX Sigilon Therapeutics
$5.97 /

-0.04 (-0.67%)

  • 04
    Dec
SGTX Sigilon Therapeutics
$5.97 /

-0.04 (-0.67%)

On The Fly
Fly Intel: Pre-market Movers » 08:56
07/09/21
07/09
08:56
07/09/21
08:56
STMP

Stamps.com

$197.78 /

+0.69 (+0.35%)

, TBLT

ToughBuilt

/

+

, NOVN

Novan

$9.10 /

+0.08 (+0.89%)

, HGEN

Humanigen

$16.66 /

+0.4 (+2.46%)

, GBX

Greenbrier

$40.09 /

-0.67 (-1.64%)

, LEVI

Levi Strauss

$28.00 /

-0.05 (-0.18%)

, DCT

Duck Creek Technologies

$41.15 /

-1.08 (-2.56%)

, SGTX

Sigilon Therapeutics

$9.24 /

+0.08 (+0.87%)

, XL

XL Fleet

$7.71 /

-0.18 (-2.28%)

Check out this morning's…

ShowHide Related Items >><<
XL XL Fleet
$7.71 /

-0.18 (-2.28%)

TBLT ToughBuilt
/

+

STMP Stamps.com
$197.78 /

+0.69 (+0.35%)

SGTX Sigilon Therapeutics
$9.24 /

+0.08 (+0.87%)

NOVN Novan
$9.10 /

+0.08 (+0.89%)

LEVI Levi Strauss
$28.00 /

-0.05 (-0.18%)

HGEN Humanigen
$16.66 /

+0.4 (+2.46%)

GBX Greenbrier
$40.09 /

-0.67 (-1.64%)

DCT Duck Creek Technologies
$41.15 /

-1.08 (-2.56%)

STMP Stamps.com
$197.78 /

+0.69 (+0.35%)

05/17/21 Northland
Stamps.com assumed at Outperform from Market Perform at Northland
01/27/21
Fly Intel: Top five analyst initiations
01/27/21 Maxim
Stamps.com assumed with a Buy at Maxim
08/07/20 Northland
Stamps.com downgraded to Market Perform from Outperform at Northland
TBLT ToughBuilt
/

+

NOVN Novan
$9.10 /

+0.08 (+0.89%)

07/09/21 Cantor Fitzgerald
Novan initiated with an Overweight at Cantor Fitzgerald
07/09/21 Cantor Fitzgerald
Novan initiated with an Overweight at Cantor Fitzgerald
06/17/21 Needham
Verrica Pharmaceuticals's Ycanth offers superior efficacy to Novan, says Needham
06/14/21 H.C. Wainwright
Novan price target raised to $28 from $20 at H.C. Wainwright
HGEN Humanigen
$16.66 /

+0.4 (+2.46%)

06/11/21 Credit Suisse
Humanigen initiated with an Outperform at Credit Suisse
05/28/21 H.C. Wainwright
Humanigen submits EUA for lenzilumab, says H.C. Wainwright
05/07/21
Fly Intel: Top five analyst initiations
05/07/21 Oppenheimer
Humanigen initiated with an Outperform at Oppenheimer
GBX Greenbrier
$40.09 /

-0.67 (-1.64%)

06/11/21 OTR Global
Railcar maker view improved to Positive from Mixed at OTR Global
12/14/20 Wells Fargo
Greenbrier upgraded to Overweight from Underweight at Wells Fargo
08/27/20
Fly Intel: Top five analyst downgrades
08/27/20 KeyBanc
Greenbrier downgraded at KeyBanc on slow rebound in domestic railcar orders
LEVI Levi Strauss
$28.00 /

-0.05 (-0.18%)

07/09/21 Evercore ISI
Levi Strauss price target raised to $40 from $36 at Evercore ISI
07/09/21 JPMorgan
Levi Strauss price target raised to $35 from $34 at JPMorgan
07/09/21 Citi
Levi Strauss price target raised to $32 from $29 at Citi
04/19/21 JPMorgan
Levi Strauss price target raised to $34 from $29 at JPMorgan
DCT Duck Creek Technologies
$41.15 /

-1.08 (-2.56%)

07/09/21 Barclays
Duck Creek Technologies price target lowered to $43 from $49 at Barclays
06/16/21 DA Davidson
Duck Creek Technologies assumed with a Buy at DA Davidson
06/10/21 RBC Capital
Duck Creek Technologies assumed with an Outperform at RBC Capital
04/22/21 Wolfe Research
Duck Creek Technologies initiated with an Outperform at Wolfe Research
SGTX Sigilon Therapeutics
$9.24 /

+0.08 (+0.87%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
XL XL Fleet
$7.71 /

-0.18 (-2.28%)

07/09/21 BTIG
XL Fleet downgraded to Neutral from Buy at BTIG
05/18/21 BTIG
XL Fleet price target lowered to $12 from $23 at BTIG
05/18/21 Canaccord
XL Fleet price target lowered to $7.50 from $10 at Canaccord
04/01/21 Canaccord
XL Fleet price target lowered to $10 from $30 at Canaccord
XL XL Fleet
$7.71 /

-0.18 (-2.28%)

STMP Stamps.com
$197.78 /

+0.69 (+0.35%)

SGTX Sigilon Therapeutics
$9.24 /

+0.08 (+0.87%)

LEVI Levi Strauss
$28.00 /

-0.05 (-0.18%)

HGEN Humanigen
$16.66 /

+0.4 (+2.46%)

GBX Greenbrier
$40.09 /

-0.67 (-1.64%)

DCT Duck Creek Technologies
$41.15 /

-1.08 (-2.56%)

  • 17
    Jun
  • 31
    Mar
  • 29
    Jan
  • 04
    Dec
  • 11
    Nov
  • 18
    Sep
  • 14
    Aug
XL XL Fleet
$7.71 /

-0.18 (-2.28%)

LEVI Levi Strauss
$28.00 /

-0.05 (-0.18%)

XL XL Fleet
$7.71 /

-0.18 (-2.28%)

STMP Stamps.com
$197.78 /

+0.69 (+0.35%)

NOVN Novan
$9.10 /

+0.08 (+0.89%)

LEVI Levi Strauss
$28.00 /

-0.05 (-0.18%)

HGEN Humanigen
$16.66 /

+0.4 (+2.46%)

GBX Greenbrier
$40.09 /

-0.67 (-1.64%)

DCT Duck Creek Technologies
$41.15 /

-1.08 (-2.56%)

XL XL Fleet
$7.71 /

-0.18 (-2.28%)

NOVN Novan
$9.10 /

+0.08 (+0.89%)

LEVI Levi Strauss
$28.00 /

-0.05 (-0.18%)

HGEN Humanigen
$16.66 /

+0.4 (+2.46%)

DCT Duck Creek Technologies
$41.15 /

-1.08 (-2.56%)

Hot Stocks
Sigilon Therapeutics falls over 20% after FDA hold on SIG-001 phase 1/2 study » 08:17
07/09/21
07/09
08:17
07/09/21
08:17
SGTX

Sigilon Therapeutics

$9.24 /

+0.08 (+0.87%)

Shares of Sigilon…

Shares of Sigilon Therapeutics are down 24.2% at $7.00 per share in pre-market trading following resumption of trade and after the FDA placed a clinical hold on the company's SIG-001 phase 1/2 study.

ShowHide Related Items >><<
SGTX Sigilon Therapeutics
$9.24 /

+0.08 (+0.87%)

SGTX Sigilon Therapeutics
$9.24 /

+0.08 (+0.87%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
SGTX Sigilon Therapeutics
$9.24 /

+0.08 (+0.87%)

  • 04
    Dec
Hot Stocks
Sigilon Therapeutics Inc trading resumes  08:00
07/09/21
07/09
08:00
07/09/21
08:00
SGTX

Sigilon Therapeutics

$9.24 /

+0.08 (+0.87%)

 
ShowHide Related Items >><<
SGTX Sigilon Therapeutics
$9.24 /

+0.08 (+0.87%)

SGTX Sigilon Therapeutics
$9.24 /

+0.08 (+0.87%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
SGTX Sigilon Therapeutics
$9.24 /

+0.08 (+0.87%)

  • 04
    Dec
Hot Stocks
Sigilon Therapeutics to resume trading at 08:00EST  07:40
07/09/21
07/09
07:40
07/09/21
07:40
SGTX

Sigilon Therapeutics

$9.24 /

+0.08 (+0.87%)

 
ShowHide Related Items >><<
SGTX Sigilon Therapeutics
$9.24 /

+0.08 (+0.87%)

SGTX Sigilon Therapeutics
$9.24 /

+0.08 (+0.87%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
SGTX Sigilon Therapeutics
$9.24 /

+0.08 (+0.87%)

  • 04
    Dec
Hot Stocks
Sigilon Therapeutics announces clinical hold on SIG-001 Phase 1/2 study » 07:31
07/09/21
07/09
07:31
07/09/21
07:31
SGTX

Sigilon Therapeutics

$9.24 /

+0.08 (+0.87%)

Sigilon Therapeutics…

Sigilon Therapeutics reported that the U.S. Food and Drug Administration has notified the Company that its Phase 1/2 study of SIG-001 in patients with severe or moderately severe hemophilia A, has been placed on clinical hold. The clinical hold was initiated following the Company's submission of a serious adverse event and temporary enrollment halt to the FDA and other regulatory agencies. To date, three patients have been dosed with SIG-001. The third patient, who received the highest dose of study drug, developed inhibitors to Factor VIII - a well-known complication of FVIII therapy. The patient is responding well to medical treatment and his condition continues to improve. Among other things, the FDA has requested additional information or data on factors potentially contributing to the development of inhibitors in this patient, such as family history and immune stimulation from a recent vaccination. All three patients enrolled in this study will continue to be followed per study protocol, while the company investigates the SAE. The status of the SAE investigation will continue to be reviewed by the Safety Review Committee for SIG-001 and Sigilon will provide additional data when available.

ShowHide Related Items >><<
SGTX Sigilon Therapeutics
$9.24 /

+0.08 (+0.87%)

SGTX Sigilon Therapeutics
$9.24 /

+0.08 (+0.87%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
SGTX Sigilon Therapeutics
$9.24 /

+0.08 (+0.87%)

  • 04
    Dec
Hot Stocks
Sigilon Therapeutics Inc trading halted, news pending  07:25
07/09/21
07/09
07:25
07/09/21
07:25
SGTX

Sigilon Therapeutics

$9.24 /

+0.08 (+0.87%)

 
ShowHide Related Items >><<
SGTX Sigilon Therapeutics
$9.24 /

+0.08 (+0.87%)

SGTX Sigilon Therapeutics
$9.24 /

+0.08 (+0.87%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
SGTX Sigilon Therapeutics
$9.24 /

+0.08 (+0.87%)

  • 04
    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.